Research programme: inflammation modulators - Inimex

Drug Profile

Research programme: inflammation modulators - Inimex

Alternative Names: Cationic peptides for inflammation - Inimex; IDRs - Inimex; IMX 002; IMX 002 compounds; Innate Defense Regulators - Inimex; Product II programme - Inimex

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inimex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Psoriasis in Canada
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top